Immatics
IMTX
Market cap $1.14B

9.54 USD

-0.08

0.83%

At close Oct 22, 4:00 PM EDT

After hours

9.50

-0.04

0.42%

1 day

-0.83%

5 days

0.21%

1 month

-18.95%

3 months

-22.75%

6 months

-6.38%

Year to date

-11.01%

1 year

20.76%

5 years

-36.61%

About: Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Employees: 343

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

162% more call options, than puts

Call options by funds: $6.39M | Put options by funds: $2.44M

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

18% more capital invested

Capital invested by funds: $762M [Q1] → $900M (+$138M) [Q2]

17% more funds holding

Funds holding: 77 [Q1] → 90 (+13) [Q2]

15% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 26

4.76% more ownership

Funds ownership: 70.36% [Q1] → 75.12% (+4.76%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$19

99%

upside

Avg. target

$19

99%

upside

High target

$19

99%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Piper Sandler

Joseph Catanzaro

44% 1-year accuracy

11 / 25 met price target

99%upside

$19

Overweight

Initiated

7 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about IMTX published over the past 30 days

Immatics: A Promising TCR Pipeline

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.

Immatics: A Promising TCR Pipeline

Immatics Announces Pricing of $150 Million Public Offering

H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.

Immatics Announces Pricing of $150 Million Public Offering

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Immatics Announces Proposed $150 Million Public Offering

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today presented the proof-of-concept clinical data for the first candidate of its next-generation, half-life extended TCR Bispecifics platform, TCER® IMA401 (MAGEA4/8), during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research.

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Zacks Investment Research

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended June 30, 2024.

Immatics Announces Second Quarter 2024 Financial Results and Business Update

See News Rankings

Charts implemented using Lightweight Charts™